Last update 01 Nov 2024

Acute Basophilic Leukemia

Last update 01 Nov 2024

Basic Info

Synonyms

Acute Basophilic Leukemia, Acute Basophilic Leukemias, Acute basophilic leukaemia

+ [18]

Introduction

A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.

Drugs associated with Acute Basophilic Leukemia

Eltrombopag Diolamine

Target

TPO receptor

Mechanism

TPO receptor agonists

Active Org.

Glaxo Wellcome SA [+10]

Originator Org.

GSK Plc

Active Indication

Anemia, Aplastic [+8]

Inactive Indication

Acute Basophilic Leukemia [+21]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date20 Nov 2008

Bevacizumab

Target

VEGF-A

Mechanism

VEGF-A inhibitors [+1]

Active Org.

National Cancer Institute [+23]

Originator Org.

Genentech, Inc.

Active Indication

Unresectable Hepatocellular Carcinoma [+189]

Inactive Indication

Acidemia, Isovaleric [+268]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date26 Feb 2004

Aldesleukin

Target

IL-2R

Mechanism

IL-2R agonists [+1]

Active Org.

National Cancer Institute [+9]

Originator Org.

Chiron Corp.

Active Indication

Renal Cell Carcinoma [+15]

Inactive Indication

Acute Basophilic Leukemia [+87]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date05 May 1992

Clinical Trials associated with Acute Basophilic Leukemia

NCT02071901 / Unknown statusPhase 2IIT

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy

This phase II trial studies how well eltrombopag olamine works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in older patients, leading to risk of complications and the delay of post-remission therapy. Eltrombopag olamine may cause the body to make platelets after chemotherapy.

Start Date14 Aug 2014

Sponsor / Collaborator

The Case Comprehensive Cancer Center

NCT01550185 / TerminatedPhase 1IIT

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia

The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse

Start Date01 May 2012

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT01627041 / Unknown statusPhase 2IIT

Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)

This randomized phase II trial studies how well decitabine works when given together with daunorubicin hydrochloride and cytarabine in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, daunorubicin hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Decitabine may help daunorubicin hydrochloride and cytarabine kill more cancer cells by making them more sensitive to the drugs. It is not yet known whether low-dose decitabine is more effective than high-dose decitabine when giving together with daunorubicin hydrochloride and cytarabine in treating acute myeloid leukemia.

Start Date16 Sep 2011

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Acute Basophilic Leukemia

100 Translational Medicine associated with Acute Basophilic Leukemia

0 Patents (Medical) associated with Acute Basophilic Leukemia

256

Literatures (Medical) associated with Acute Basophilic Leukemia

01 Mar 2024·Ultramicroscopy

The target region focused imaging method for scanning ion conductance microscopy

Article

Author: Zhuang, Jian ; Hu, Shiting ; Gu, Shengbo ; Wang, Tianying ; Song, Weilun ; Liao, Xiaobo

Scanning ion conductance microscopy (SICM) has developed rapidly and has wide applications in biomedicine, single-cell science and other fields. SICM scanning speed is limited by the conventional raster-type scanning method, which spends most of time on imaging the substrate and does not focus enough on the target area. In order to solve this problem, a target region focused (TRF) method is proposed, which can effectively avoid the scanning of unnecessary substrate areas and enables SICM to image the target area only to achieve high-speed and effective local scanning. TRF method and conventional hopping mode scanning method are compared in the experiments using breast cancer cells and rat basophilic leukemia cells as experimental materials. It was demonstrated that our method can reduce the scanning time for a single sample image significantly without losing scanning information or compromising the quality of imaging. The TRF method developed in this paper can provide an efficient and fast scanning strategy for improving the imaging performance of SICM systems, which can be applied to the dynamic features of cell samples in the fields of biology and pharmacology analysis.

01 Dec 2023·International Journal of Laboratory Hematology

Acute basophilic leukemia in a patient with down syndrome: A case report and review of literature

Review

Author: More, Manisha ; Shetty, Dhanlaxmi ; Subramanian, Papagudi G ; Gujral, Sumeet ; Singh, Anu ; Chatterjee, Gaurav ; Patil, Jagruti ; Rajpal, Sweta ; Tembhare, Prashant R ; Patkar, Nikhil V

01 Sep 2023·Clinical laboratory

Complex Karyotype Acute Basophilic Leukemia with Reactive Mast Cell Hyperplasia.

Author: Li, Ruimin ; Wu, Yiping ; Zhang, Xiaofang ; Guo, Hongxia ; Guo, Jia

BACKGROUNDThe goal of the study is to improve the understanding of complex karyotype acute basophilic leukemia with reactive mast cell hyperplasia.METHODSA case of clinical and laboratory characteristics of complex karyotype acute basophilic leukemia with reactive mast cell hyperplasia and review of related literature of patient with acute basophilic leukemia were retrospectively analyzed.RESULTSLaboratory tests: alanine aminotransferase 225 U/L, aspartate aminotransferase 129 U/L, total protein 3.0 g/L, albumin 25.0 g/L, globulin 17.8 g/L, total bilirubin 183.9 μmol/L, indirect bilirubin 65.6 μmol/L, D-dimer 13.02 mg/L, prothrombin time 19.30 S, white blood cell 37.30 x 109/L, red blood cells 2.06 x 1012/L, hemoglobin 71 g/L, platelets 13 x 109/L, and basophilic granulocyte cells 5.01 x 109/L. Bone marrow smear: a large number of abnormal primitive cells were scattered and distributed. The characteristics of these cells were as follows: the cell body size was different, most of them were round or quasi-round, the cytoplasm volume was medium, and the cytoplasm was stained gray blue. The cytoplasmic processes were visible, and basophilic particles were visible in part of the cytoplasm and/or on the nucleus. The nuclei were mostly round or almost round, with distortion and folding. The chromatin was detailed, the nucleoli varied in number, and some nucleoli were deeply stained. The cells showed double and multiple nuclei, scattered and occasionally small clumps. Bone marrow biopsy: acute myeloid leukemia, not excluding basophilic leukemia. Bone marrow molecular biology: All 29 myeloid leukemia genes, including RARA and BCR-ABL fusion genes, were negative. Flow cytometry results showed abnormal cell population which accounted for 21.98% of nuclear cells. The phenotypes are CD33++, CD38+, CD13+, CD123+, CD7+, CD36+, CD203c+, CD81+, part of CD34+, part of HLA-DR+, CD4 weak+, weak CD117+, the TDT-, cCD3-, cCD79a-, MPO-, CD11c-, CD25-, CD2-. In addition, mast cells accounted for 1.15% of nuclear cells, expressing CD203c, but not CD25 and CD2. Karyotype analysis results were 46, XY, -7, psudic (9; 19) (p24; p13.3), add (15) (p12), add (21) (q22), +r, +1 - 2 mar [cp20].CONCLUSIONSAcute basophilic leukemia (ABL) is a rare malignant hematologic tumor. Bone marrow smears, biopsies, flow cytometry, and cytogenetic tests play an important role in the diagnosis and differentiation of complex karyotype acute basophilic leukemia with reactive mast cell hyperplasia.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Acute Basophilic Leukemia

Basic Info

Related

Analysis